Hartford Investment Management Co. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 10,330 shares of the company’s stock after selling 154 shares during the period. Hartford Investment Management Co.’s holdings in IDEXX Laboratories were worth $1,922,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Security Asset Management lifted its holdings in IDEXX Laboratories by 0.4% in the fourth quarter. Security Asset Management now owns 15,245 shares of the company’s stock valued at $2,836,000 after acquiring an additional 60 shares during the last quarter. ETF Managers Group LLC boosted its stake in shares of IDEXX Laboratories by 15.8% during the fourth quarter. ETF Managers Group LLC now owns 682 shares of the company’s stock worth $127,000 after buying an additional 93 shares during the period. Dupont Capital Management Corp raised its holdings in IDEXX Laboratories by 28.3% during the fourth quarter. Dupont Capital Management Corp now owns 1,677 shares of the company’s stock worth $312,000 after purchasing an additional 370 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in IDEXX Laboratories by 4.7% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,192 shares of the company’s stock worth $222,000 after purchasing an additional 54 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS raised its holdings in IDEXX Laboratories by 19.8% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 159,181 shares of the company’s stock worth $29,611,000 after purchasing an additional 26,345 shares in the last quarter. Institutional investors and hedge funds own 87.41% of the company’s stock.

A number of brokerages recently issued reports on IDXX. Canaccord Genuity decreased their target price on shares of IDEXX Laboratories from $270.00 to $250.00 and set a “buy” rating on the stock in a research report on Monday, November 5th. Bank of America dropped their target price on shares of IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, November 2nd. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $236.00 price target for the company in a report on Monday, February 4th. Finally, BidaskClub raised shares of IDEXX Laboratories from a “sell” rating to a “hold” rating in a report on Thursday, January 24th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. IDEXX Laboratories currently has an average rating of “Buy” and a consensus price target of $246.00.

NASDAQ IDXX opened at $207.74 on Monday. IDEXX Laboratories, Inc. has a 12 month low of $166.70 and a 12 month high of $256.22. The company has a market capitalization of $17.91 billion, a P/E ratio of 48.77 and a beta of 1.02.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Friday, February 1st. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.08. IDEXX Laboratories had a net margin of 17.03% and a negative return on equity of 1,501.97%. The business had revenue of $549.39 million for the quarter, compared to the consensus estimate of $546.04 million. During the same period in the previous year, the firm earned $0.43 EPS. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, analysts predict that IDEXX Laboratories, Inc. will post 4.69 earnings per share for the current fiscal year.

In other news, CEO Jonathan W. Ayers sold 15,905 shares of the business’s stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $208.13, for a total transaction of $3,310,307.65. Following the sale, the chief executive officer now owns 1,047,226 shares in the company, valued at $217,959,147.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lawrence D. Kingsley purchased 2,405 shares of the business’s stock in a transaction dated Tuesday, February 5th. The shares were purchased at an average price of $208.68 per share, for a total transaction of $501,875.40. Following the acquisition, the director now directly owns 7,403 shares of the company’s stock, valued at $1,544,858.04. The disclosure for this purchase can be found here. Insiders sold a total of 20,406 shares of company stock worth $4,201,760 over the last quarter. Insiders own 2.56% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Hartford Investment Management Co. Sells 154 Shares of IDEXX Laboratories, Inc. (IDXX)” was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.watchlistnews.com/hartford-investment-management-co-sells-154-shares-of-idexx-laboratories-inc-idxx/2812816.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.